PATENT CLAIM ANALYSIS

Application Number: 15764794
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "210210"]

Abstract:
The present disclosure relates to solid dosage forms comprising anti-HCV compounds and methods of using such dosage forms to treat or prevent HCV infection. Direct-acting antiviral agents (DAAs) have a high cure rate, and favorable tolerability in persons infected with hepatitis C virus (HCV). However, shorter courses of therapy can improve adherence, affordability, and increase DAAs accessibility. The addition of an NS3 protease inhibitor to dual NS5A-NS5B (nucleoside) inhibitors enhances antiviral efficacy, and reduces treatment duration to 3 weeks (wks) in individuals with a rapid virologic response (RVR), defined as plasma HCV RNA<500, or <1,000, IU/mL by Day 2 of treatment.

Claim (Index 9):
The formulation of  claim 9 , wherein the JAK inhibitor is Ruxolitinib Baracitinib, or Tofacitinib.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 90.0
- Lexical Diversity: 1.46512
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15885630', '13726783', '13935983', '13935987', '13656012']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7351792002989349
- 35 USC 102 Novelty (BERT): 0.5302875483457637
- Combined Prediction Score: 0.7146900351036178
- Mean Citation Score: 264.019582
- Max Citation Score: 286.44485
- Similarity Product: 158.31420516156254

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test